Share
Milton Boyer
Kindeva, a global contract development and manufacturing organization (CDMO) and innovator in drug delivery solutions, has announced a series of planned leadership transitions aimed at accelerating growth across its core parenteral and inhaled drug delivery businesses.
As part of the transition, Milton Boyer has stepped down from his role as Chief Executive Officer and will continue to serve as an independent member of Kindeva’s Board of Directors. In this capacity, he will provide strategic guidance and ensure continuity as the company executes its long-term growth strategy.
These leadership changes conclude a structured succession plan initiated in October 2025 and reflect Kindeva’s commitment to stability, continuity, and sustained value creation. The transition reinforces the company’s focus on strengthening its core capabilities while positioning Kindeva for long-term success in the evolving global pharmaceutical landscape.
